IDP.L

InnovaDerma Plc
InnovaDerma PLC - Extension to Annual Report & Accounts Publication
22nd October 2021, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8830P
InnovaDerma PLC
22 October 2021
 

InnovaDerma PLC

 ("InnovaDerma" or the "Company")

 

Extension to Annual Report and Accounts publication deadline

InnovaDerma (LSE: IDP) expects to announce its audited results to 30 June 2021 in December 2021. This represents an extension to the usual timetable following the granting by the Financial Conduct Authority of a temporary relief to the reporting deadline. This is due to the impact of Covid-19 lockdowns in the UK, Australia and Philippines, and timely access to information from the Company's previous auditors.

The Company confirms the headline financials for the year ended 30 June 2021 remain unchanged from those announced on 8 July 2021. The focus remains on higher gross margins, enhanced new product development pipeline and stronger cost control as Innovaderma transitions to sustainable, profitable growth.

Trading remains in line with market expectations for the year ending 30 June 2022.

 

Further enquiries

InnovaDerma

Blake Hughes

 

c/o TB Cardew

finncap Ltd

Geoff Nash/Kate Bannatyne

Alice Lane - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

 

Shan Shan Willenbrock/

+ 44 (0)7775 848537

Olivia Rosser

+ 44 (0)7552 864250

 

innovaDerma@tbcardew.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFLLIDLLFIL ]]>
TwitterFacebookLinkedIn